Alembic Pharma (Oral Solids ==> Injectables, Onco, Derma, Opthalmic)

TG Therapeutics voluntarily withdraws its UKONIQ approval for applications in marginal zone lymphoma (MZL) and follicular lymphoma (FL) that it had received from US FDA in February 2021. This is based on recent data for Unity Phase 3 trials. Although, the product never accounted for large part of Alembic’s revenues as it was in build up phase, its a little sad as this was the first NDA approval for a drug developed by Indian scientists. The detailed press release is below.

Disclosure: Invested (position size here, bought few shares in last 30 days)

Updates: As I read through the press release, it seems that the initial Phase 3 study had passed the primary endpoint. However, there was a secondary endpoint which wasn’t met initially, company claims that this was because the trials were not designed to collect that data properly. FDA wanted to be sure that the secondary end point was also met and they called a committee to judge the scientific appropriatness of the same while judging a subsequent BLA/sNDA application by TG Therapeutics. For this new application, there was another trial which was organized where the secondary data point was properly collected. As results of the secondary data point was analyzed, company realized that the therapy doesn’t do what its supposed to do. Thus, they withdrew their new application and along with retracting their older approval.
Note: I might have oversimplified this explanation, this is what the press release kind of says. Although, I am not a biology/drug expert, so please read the press release for yourself at the link above.

1 Like

Takeaway from results:

  • Topline up 10.5% YoY
  • EBITDA margins are down significantly. All costs are in line except depreciation, and other expenses, which explains margins.
  • Headline PAT is down from ~250 Cr. to 30 Cr.

Note 6 explains why:

If we adjust for the one off expense:

  • Amortisation of 65 Cr. and 123 Cr. in other expenses.
  • PAT of 180 Cr., down ~28% YoY.

Other notes:

  • India branded business grew 25% YoY. Acute portfolio has grown 57%.
  • US generics see an uptick, one new product launch. Expecting 15+ launches in FY23. (Is the pain period behind US generics companies?)
  • R&D spend is highest in the last 5 years, 15.8% of sales in FY22.
12 Likes

The updated numbers are below. Some of the major highlights for me were:

  • ANDA filing rate has been maintained. US revenue per launch reduced drastically from 23.5 cr. in FY21 to 15.87 cr. in FY22
  • Gross margins were at ~73%, with all the pricing pressure they were able to maintain good gross margins
  • Domestic market is doing very well which is a reflection of change in strategy (MR productivity increased from 30 lakh in FY21 to 35 lakhs in FY22 + 500 new MRs were added).
  • Alembic Pharma was able to get one new brand in top 300. Domesti market share has increased slightly from 1.4% in FY21 to 1.5% in FY22 (mostly because of very strong growth in azithral which crossed 450 cr. sales in 2021)
  • Changed 3PL distributor in USA
  • In domestic markets, company doesn’t focus on new to market launches. The approach is to gain market share gradually in already existing molecules
  • US growth has been due to increase in market share in some products + few shortages
  • Indian brands are currently valued very highly, not ready to acquire at these multiples
  • High R&D is because of accelerated amortization of R&D costs from Aleor
FY16 FY17 FY18 FY19 FY20 FY21 FY22
Cumulative ANDA filed 76.00 96.00 132.00 161.00 183.00 212.00 230.00
Cumulative ANDA approved (tentative excluded) 42.00 46.00 61.00 77.00 107.00 123.00 138.00
Products commercialized 34.00 37.00 44.00 53.00 76.00 92.00 105.00
Products commercialized (own frontend) 86.00
DMF filing 81.00 90.00 94.00 100.00 109.00 117.00 125.00
Consolidated revenue 3’181.20 3’134.00 3’131.00 3’935.00 4’606.00 5’393.00 5’306.00
US revenues (mn $) 130.38 177.56
India 1’103.60 1’254.00 1’274.00 1’382.00 1’425.00 1’497.00 1’926.00
International formulations 1’461.50 1’236.00 1’206.00 1’782.00 2’473.00 2’942.00 2’441.00
International generics
International branded
US 1’227.66 919.00 920.00 1’288.00 1’976.00 2’163.00 1’666.00
Non-US 233.84 317.00 286.00 494.00 497.00 779.00 775.00
Export incentives
APIs 524.90 643.00 651.00 771.00 708.00 955.00 939.00
R&D expense 10.88% 13.72% 13.09% 12.66% 14.00% 12.42% 15.80%
R&D (cr.) 346.00 430.00 410.00 498.00 645.00 670.00 838.35
CAPEX 320.00 480.00 600.00 626.00 697.00 687.00 467.00
EBITDA margin 31.62% 19.56% 20.50% 22.24% 26.34% 30.24% 18.00%
PAT margin 22.61% 12.73% 13.06% 14.84% 18.00% 21.84% 10.29%
Debt
ROCE (excluding new projects) 53.00% 27.00% 25.00% 30.00% 32.00% 41.00% 19.00%
Indian MR count 5’000.00 5’000.00 5’000.00 5’000.00 5’000.00 5’000.00 5’500.00
India acute share 37.00% 33.00% 34.00% 33.00% 36.11%
India specialty share 54.00% 58.00% 56.00% 57.00% 52.78%
India vet share 9.00% 9.00% 10.00% 10.00% 11.11%
India market share 1.73% 1.50% 1.57% 1.50% 1.40% 1.50%
India (brands in top 100)
India (brands in top 300) 5.00 5.00 5.00 5.00 3.00 2.00 3.00
India revenue per MR (lakh / year) 22.07 25.08 25.48 27.64 28.50 29.94 35.02
US revenue (mn $) per launch 2.96 3.35
US revenue (cr) per launch 36.11 24.84 20.91 24.30 26.00 23.51 15.87
US revenue (cr) per accepted 29.23 19.98 15.08 16.73 18.47 17.59 12.07

Disclosure: Invested (position size here, no transactions in last 30-days)

15 Likes

Here are my notes from their condensed annual report (link)

Manufacturing facilities:

  • 9 manufacturing facilities (total 6 formulation plants + 3 API plants), 3 awaiting regulatory approvals (same as FY21)
  • F1 (Panelav): Oral solids
  • F2 (Panelav): Oncology oral solids (approved; commercial products are Para-IV opportunities awaiting patent expiry) + oncology injectables (awaiting regulatory approval; filed 4 ANDAs)
  • F3 (Karkhadi): General injectables (10 observations pushes back commercialization by few months; filed 15 ANDAs) + Ophthalmic (awaiting regulatory approval)
  • F4 (Jarod): Oral solids (awaiting regulatory approval)
  • Aleor (Karkhadi): Dermatology
  • Sikkim: Branded domestic business
  • 3 API plants (Panelav, Karkhadi)

US (sales: 1’666 cr., de-growth @(-23%))

  • Launched 13 products (vs 16 in FY21), filed 23 ANDAs (vs 29 in FY21), got 15 final approvals (vs 16 in FY21), filed 8 DMFs (same in FY21)
  • Top-5 suppliers in 62 products (vs 47 in FY21)
  • Witnessed steep pricing pressure in FY22
  • FY22 is the new base and company will grow by launching new products. Plan to file 25 ANDAs annually and launch 15 products (OSD, injectables, ophthalmic, derma)
  • Pipeline of 131 ANDAs
  • Filling rates have stayed at 97-98% in last 3-years leading to high reliability. Refused few customers where back end supply chain was fully occupied
  • Aleor became wholly owned subsidiary (paid 76 cr. for 40% stake; FY22 sales: 38.9 cr.). Expensed out 188 cr. in intangible assets
  • Competitive pressure in derma space has increased significantly. Aleor is positioned as a low cost manufacturer

Non-US generic (sales: 775 cr., de-growth @(-1%))

  • 149 filings
  • Have presence in 20+ countries in Europe. Mostly tender driven market
  • Australia: Few distributors control entire market. Currently have 23 dossiers commercialized or approved
  • South Africa: Ventured in 2014, have witnessed success recently. Currently have 23 dossiers commercialized or approved
  • Looking to venture in LATAM, filing aggressively in South-east Asian markets

Domestic business (sales: 1’926 cr., growth @29% vs 18% for industry)

  • 10 therapeutic areas (vs 10 in FY21), 18 (vs 17 in FY21) marketing divisions, 5500+ MRs (vs 5’000 in FY21) catering to 2.22 lakh doctors (vs 1.75 lakh in FY21)
  • Launched 5 new products
  • 1.51% market share (vs 1.4% in FY21), 3 brands in top-300 (vs 2 in FY21). 9-10 brands generating 50 cr.+ sales
  • Gained due to COVID and black fungus (azithral, amphotericin)
  • 21.5% (vs 19% in FY21) product in NLEM, 64% (vs 69% in FY21) of sales came from chronic and 36% (vs 31% in FY21) from acute
  • Have revamped complete Indian MR team and infused young talent directly from colleges. 66% of field force is under 30
  • Migrated stockist to lower inventory model which led to higher demand-pull thereby improving MR attrition
  • Registered strong growth in women healthcare portfolio

API (sales: 939 cr., de-growth @(-2%))

  • Ex-azithromycin portfolio grew well
  • Manufactures 100 APIs, 38% captive consumption (vs 33% in FY21)

R&D (15.8% of sales vs 12.4% in FY21)

  • 838 cr. (vs 694 cr. in FY21), 90% of R&D spends are targeted towards US market
  • Created a dedicated technology transfer team to facilitate seamless DMF/ANDA filing
  • Three R&D segments – formulations, API and peptides
  • Company has created a peptide R&D unit a few years back to develop peptide APIs for complex injectables. Company has built 100% in-house capability in doing characterization of peptide-based injectables
  • Intensified efforts to maximize solvent recovery, reducing consumption of fresh solvent in manufacturing process. Residue generated in the solvent recovery process, which used to be incinerated earlier, is now sent to cement factories in vicinity
  • 1200+ R&D employee strength (same as last year)
  • Facilities in Vadodara, Hyderabad and New Jersey
    o Vadodara unit is the mainstay innovation center developing non-oncology molecules
    o Hyderabad unit develops oncology and non-oncology molecules
    o US unit is focused on developing and filing oral solids and liquid products. It adds complimentary skill sets in soft gelatin based oral solids and oral liquids

Capex (482 cr. vs 687 cr. in FY21)

  • Have cumulatively invested 3’000+ cr. over last 5-years

Financials

  • Revenues de-grew by (-2%) to 5’306 cr., EBITDA margins: 18% (vs 30% in FY21), PAT margins: 10% (vs 22% in FY21), R&D: 15.8% of sales (vs 12% in FY21), ROCE (excluding new projects): 19% (vs 41% in FY21), ROE: 11% (vs 23% in FY21), Debt to equity: 0.12 (vs 0.1 in FY21)

Miscellaneous

  • Hedge 35-40% of net exposure
  • Employees: 11’974 (vs 12’160 in FY21)
  • KMP remuneration (including close members to KMP): 86 cr. (vs 88 cr. in FY21)
  • Related party purchases from Shreno Publications: 31.96 cr. (vs 26.16 cr. in FY21)
  • CSR: Spent 22 cr. (vs 17.6 cr. in FY21) (no outstanding obligations)
  • Shareholders: 108’622 (vs 101’950 in FY21)
  • Auditor remuneration: 1.51 cr. (vs 1.4 cr. in FY21)
  • Contingent liability: No major liability except corporate guarantee of 61.35 cr. (vs 96.04 cr. in FY21)

Disclosure: Invested (position size here, bought shares in last-30 days)

14 Likes


APL CWIP is more than β€œnet asset”. Many of the projects have started 3 years back.

I wonder if we have the list of projects which are under construction, time line for
starting operations, and expected asset turn over.

2 Likes